US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Militia Long/Short Equity ETF

37.12

+0.21280.58%

Volume:98.43K

Turnover:3.66M

Market Cap:338.53M

PE:- -

High:37.45

Open:36.96

Low:36.87

Close:36.91

52wk High:39.39

52wk Low:29.50

Shares:9.12M

Float Shares:9.12M

Volume Ratio:3.27

T/O Rate:1.08%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Press Release: Samsung Epis Holdings Reports Second Quarter and Half-year 2026 Financial Results

Press Release: Harbour Biomed Announces Positive Profit Alert for 2026 Interim Results, Marking Seventh Consecutive Profitable Half-year as Platform-based Advantages Drive Sustainable Growth

Oriole Completes Maiden Drilling at Cameroon Limestone Asset to Target Cement Market

Press Release: Standard Biotools Announces Filing of Registration Statement in Connection with Treeline Biosciences Transaction

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ORR"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ORR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","market":"US","secType":"STK","nameCN":"Militia Long/Short Equity ETF","latestPrice":37.12,"timestamp":1785175926060,"preClose":36.9072,"halted":0,"volume":98430,"delay":0,"changeRate":0.0057658126327652685,"floatShares":9120000,"shares":9120000,"eps":0,"marketStatus":"Trading","change":0.2128,"latestTime":"07-27 14:12:18 EDT","open":36.96,"high":37.45,"low":36.87,"amount":3660130.3773000003,"amplitude":0.015715,"askPrice":37.31,"askSize":47,"bidPrice":36.99,"bidSize":124,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1785182400000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":36.9072,"sharesOutstanding":12900000,"nav":36.89,"aum":336436800,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":36.51,"preClose":36.9072,"latestTime":"08:07 EDT","volume":1,"amount":36.51,"timestamp":1785154068118,"change":-0.3972,"changeRate":-0.010762,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":36.95,"preClose":36.9072,"latestTime":"19:34 EDT","volume":110,"amount":4055.1532,"timestamp":1784936051678,"change":0.0428,"changeRate":0.00116,"amplitude":0},"volumeRatio":3.271753,"impliedVol":0.1508,"impliedVolPercentile":0.6087},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","floatShares":9120000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":3.271753,"shares":9120000,"dividePrice":0,"high":37.45,"amplitude":0.015715,"preClose":36.9072,"low":36.87,"week52Low":29.5,"pbRate":"--","week52High":39.39,"institutionHeld":0,"latestPrice":37.12,"committee":0.450292,"eps":0,"divideRate":0,"volume":98430,"delay":0,"ttmEps":0,"open":36.96,"prevYearClose":34.16,"prevWeekClose":36.9072,"prevMonthClose":36.32,"prevQuarterClose":36.32,"fiveDayClose":36.74,"twentyDayClose":36.07,"sixtyDayClose":35.23},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ORR\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ORR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ORR\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ORR\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2653704593","title":"Press Release: Samsung Epis Holdings Reports Second Quarter and Half-year 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2653704593","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653704593?lang=en_us&edition=fundamental","pubTime":"2026-07-24 15:20","pubTimestamp":1784877600,"startTime":"0","endTime":"0","summary":"--  Samsung Bioepis reports revenue of 847.1 billion KRW and an operating. profit of 230.6 billion KRW in the first half of 2026, recording 6%. --  Expanding direct commercialization in Europe to five products with the. launch of OPUVIZ 40 mg/mL vial, a biosimilar to Eylea1 . --  First to announce preliminary results from Phase 1, 3 clinical studies. engines through establishment of a global R&D hub in China. -----------------  -----  -----  ----------  -----  -----  ----------Business Updates--  Samsung Bioepis has expanded direct commercialization in Europe to five. expanding its commercial footprint in international markets, incl","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4604","CEO","KBWY","BK4080","BK4504","BK4555","IEMG","ORR","BBP","BK4181","BK4585","BK4232","BK4022","BK4550","NETL","R","03160","EMXC","BK4588","BK4218","BK4231","BK4581","BK4099","TM","PK","ADC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653774076","title":"Press Release: Harbour Biomed Announces Positive Profit Alert for 2026 Interim Results, Marking Seventh Consecutive Profitable Half-year as Platform-based Advantages Drive Sustainable Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2653774076","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653774076?lang=en_us&edition=fundamental","pubTime":"2026-07-24 08:03","pubTimestamp":1784851380,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, July 23, 2026 /PRNewswire/ -- Harbour BioMed , a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced a positive profit alert for the six months ended June 30, 2026 .Based on a preliminary review of the Company's unaudited management accounts for the Reporting Period, the revenue is expected to range between US$120 million  and US$125 million , representing an increase of approximately 19% to 24% compared with approximately US$101 million for the corresponding period in 2025. The profit for the Reporting Period is expected to range between US$62 million  and US$67 million . Total adjusted profit ([1]) is expected to range between US$70 million  and US$75 million .The expected revenue growth and scaled profitability are primarily attributable to:-- Continued strategic collaborations with global multinational","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MSS","03160","BK4585","BK1161","AIPO","02142","ORR","BK1583","BK1574","BMS","BK4555","BK4113","CHAT","CNS","BK4135","BK4232","BK4099","TM","VTHR","BK4588","R","ARTY","AGIX","BK4022","BK4604","QTOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653734922","title":"Oriole Completes Maiden Drilling at Cameroon Limestone Asset to Target Cement Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2653734922","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653734922?lang=en_us&edition=fundamental","pubTime":"2026-07-22 14:12","pubTimestamp":1784700739,"startTime":"0","endTime":"0","summary":"An update from Oriole Resources PLC ( ($GB:ORR) ) is now available. Oriole Resources PLC has completed a maiden diamond drilling programme at its 8...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/oriole-completes-maiden-drilling-at-cameroon-limestone-asset-to-target-cement-market?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/oriole-completes-maiden-drilling-at-cameroon-limestone-asset-to-target-cement-market?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ORR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652001290","title":"Press Release: Standard Biotools Announces Filing of Registration Statement in Connection with Treeline Biosciences Transaction","url":"https://stock-news.laohu8.com/highlight/detail?id=2652001290","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652001290?lang=en_us&edition=fundamental","pubTime":"2026-07-20 19:30","pubTimestamp":1784547000,"startTime":"0","endTime":"0","summary":"Highlights combined company's strong financial position with over $900 million expected at closing, Treeline's deep clinical-stage pipeline, planned 2027 data updates for TLN-121 and TLN-372, and expe","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","SMP","CR","BK4124","BK4161","ORR","LAB"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":29,"pageCount":1,"totalSize":113,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/ORR\",params:#limit:6,delay:false,,,undefined,":[]}}